Protein / target
NT-3 growth factor receptor
Protein at a glance
Biological role
Transmembrane receptor protein tyrosine kinase activity
Primary system
Nervous system
Strongest disease association
ovarian neoplasm
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
6 approved · 7 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Receptor tyrosine kinase involved in nervous system and probably heart development. Upon binding of its ligand NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different signaling pathways, including the phosphatidylinositol 3-kinase/AKT and the MAPK pathways, that control cell survival and differentiation
Subcellular location
Domains and Gene Ontology detail (39)Hide
Domains & features
Gene Ontology
- Caxon
- Ccytoplasm
- Cglutamatergic synapse
- Cnucleolus
- Cplasma membrane
- Cpostsynaptic membrane
- Creceptor complex
- FATP binding
- FGPI-linked ephrin receptor activity
- Fneurotrophin binding
- Fneurotrophin receptor activity
- Fp53 binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Synaptic signalling
- ·glutamatergic synapse
- ·postsynaptic membrane
- ·postsynaptic density assembly
- ·regulation of presynapse assembly
Kinase signalling
- ·transmembrane receptor protein tyrosine kinase activity
- ·positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction
Excitatory neurotransmission
- ·glutamatergic synapse
Transcriptional regulation
- ·positive regulation of gene expression
View underlying pathways (10)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
NT-3 growth factor receptor inhibitor
Appears in clinical studies involving non-small cell lung carcinoma, non-small cell lung carcinoma, non-small cell lung carcinoma, cancer
Neurotrophic tyrosine kinase receptor inhibitor
Appears in clinical studies involving neoplasm, cancer, plasma cell myeloma, lymphoma
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Highest overall evidence
Remaining associations by Open Targets' aggregated evidence score.
Show all associationsHide all associations
Open Targets ranks 2,978 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 13 total
non-small cell lung carcinoma · non-small cell lung carcinoma · neoplasm
non-small cell lung carcinoma · non-small cell lung carcinoma · neoplasm
malignant pancreatic neoplasm
neoplasm · cancer · plasma cell myeloma
metastasis · cancer · neoplasm
non-small cell lung carcinoma · non-small cell lung carcinoma · non-small cell lung carcinoma
cancer · pancreatic ductal adenocarcinoma · hematopoietic and lymphoid system neoplasm
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
Show remaining trials (16)Hide
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through 2 drugs that target this protein, so each event is news about that drug rather than about the protein directly.
- Regulatory approval
Approval: Augtyro (EMA)
- New publicationRepotrectinib in <i>ROS1</i> Fusion-Positive Non-Small-Cell Lung Cancer.
- New publicationEfficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.